Blood
Articles in this Issue
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
Abstract CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and recently showed...
Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Abstract The prognosis for relapsed or refractory (R/R) nucleophosmin 1–mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a...
RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation
Abstract The recurrent t(1;22) translocation in acute megakaryoblastic leukemia (AMKL) encodes the RBM15-MKL1 fusion protein. Dysregulation of the N6-methyladenosine (m6A) modifica...
LRRC8 complexes are ATP release channels that regulate platelet activation and arterial thrombosis
Abstract Platelet shape and volume changes are early mechanical events contributing to platelet activation and thrombosis. Here, we identify single-nucleotide polymorphisms in leucin...
Meddling with METTL3 in acute megakaryoblastic leukemia
Driving CAR-Ts SafeSLE
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma
Abstract Modakafusp alfa is a first-in-class immunocytokine-directing interferon alfa to CD38+ cells. Our previous phase 1/2 trial identified 2 potential phase 2 doses of modakafusp...
Hole in one: CD137-ADC eliminates GVHD
Clone wars: the expansion menace
NPM1: the ultimate target in AML
LRRC8 links platelet stretching to local arterial thrombosis
Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women
Abstract Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased mortality and malignancy risk, yet the determinants of clonal expansion remain poorly und...
A single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD
Abstract Rapid CD137 upregulation on alloreactive T cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD)...
Immune alterations in myeloma evolution and outcomes: quo vadis?
Abstract The pathogenesis of multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS) is linked to an aging immune system. Chronic activation...